TYK Medicines (HKG:2410) said the results from a mid-stage study of its experimental cancer drug TY-9591 were accepted for mini oral presentation at the World Conference on Lung Cancer, according to a Thursday filing with the Hong Kong bourse.

The company will present interim results from the Esaona phase 2 study in subjects with EGFR-mutant non-small cell lung cancer.

The study is examining how well TY-9591, or asandeutertinib, works when compared to osimertinib in previously untreated patients.

Based on data available as of Feb. 28, asandeutertinib had a superior objective response rate of 84.7% versus osimertinib's 75.2% in patients whose cancer had spread to the brain, the company said.